Last reviewed · How we verify

Ad26.ZEBOV 2*10^10 (vp)

Janssen Vaccines & Prevention B.V. · Phase 3 active Biologic

Ad26.ZEBOV 2*10^10 (vp) is a Viral vector vaccine Biologic drug developed by Janssen Vaccines & Prevention B.V.. It is currently in Phase 3 development for Ebola virus disease prevention, Post-exposure prophylaxis for Ebola virus exposure.

Ad26.ZEBOV is a replication-incompetent adenovirus serotype 26 vector expressing the Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus.

Ad26.ZEBOV is a replication-incompetent adenovirus serotype 26 vector expressing the Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus. Used for Ebola virus disease prevention, Post-exposure prophylaxis for Ebola virus exposure.

At a glance

Generic nameAd26.ZEBOV 2*10^10 (vp)
SponsorJanssen Vaccines & Prevention B.V.
Drug classViral vector vaccine
TargetEbola virus glycoprotein (GP)
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

This vaccine uses a non-replicating adenoviral vector to deliver genetic instructions for producing the Ebola virus surface glycoprotein, triggering both cellular and humoral immune responses. The Ad26 vector is designed to be immunogenic while unable to replicate, making it a safe platform for vaccine delivery. It is typically used as a prime in heterologous prime-boost vaccination regimens against Ebola virus disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ad26.ZEBOV 2*10^10 (vp)

What is Ad26.ZEBOV 2*10^10 (vp)?

Ad26.ZEBOV 2*10^10 (vp) is a Viral vector vaccine drug developed by Janssen Vaccines & Prevention B.V., indicated for Ebola virus disease prevention, Post-exposure prophylaxis for Ebola virus exposure.

How does Ad26.ZEBOV 2*10^10 (vp) work?

Ad26.ZEBOV is a replication-incompetent adenovirus serotype 26 vector expressing the Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus.

What is Ad26.ZEBOV 2*10^10 (vp) used for?

Ad26.ZEBOV 2*10^10 (vp) is indicated for Ebola virus disease prevention, Post-exposure prophylaxis for Ebola virus exposure.

Who makes Ad26.ZEBOV 2*10^10 (vp)?

Ad26.ZEBOV 2*10^10 (vp) is developed by Janssen Vaccines & Prevention B.V. (see full Janssen Vaccines & Prevention B.V. pipeline at /company/janssen-vaccines-prevention-b-v).

What drug class is Ad26.ZEBOV 2*10^10 (vp) in?

Ad26.ZEBOV 2*10^10 (vp) belongs to the Viral vector vaccine class. See all Viral vector vaccine drugs at /class/viral-vector-vaccine.

What development phase is Ad26.ZEBOV 2*10^10 (vp) in?

Ad26.ZEBOV 2*10^10 (vp) is in Phase 3.

What are the side effects of Ad26.ZEBOV 2*10^10 (vp)?

Common side effects of Ad26.ZEBOV 2*10^10 (vp) include Injection site pain or erythema, Fatigue, Myalgia, Headache, Fever.

What does Ad26.ZEBOV 2*10^10 (vp) target?

Ad26.ZEBOV 2*10^10 (vp) targets Ebola virus glycoprotein (GP) and is a Viral vector vaccine.

Related